Document:

Exhibit 4.1

  

NEITHER THIS
SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF
COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY
AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER
LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

 

Interleukin
Genetics, Inc.

 

 

	Warrant
    Shares: [_______]	July
    29, 2016

 

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [_____________] (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after the Initial Exercise Date (as defined below), and on or prior to the close of business on the seven (7) year anniversary
of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from
Interleukin Genetics, Inc., a Delaware corporation (the “Company”), up to [___________] shares (the “Warrant
Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b). The “Initial Exercise Date” shall mean the date hereof.

 

Section
1.                  Definitions.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase
Agreement (the “Purchase Agreement”), dated July 29, 2016, among the Company and the purchasers signatory thereto.

 

Section
2.                   Exercise.

 

a)                 
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part,
at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or
such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of
the Holder appearing on the books of the Company) of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto;
and, within three (3) Trading Days of the date said Notice of Exercise is delivered to the Company, the Company shall have received
payment in the amount obtained by multiplying the Exercise Price then in effect by the number of Warrant Shares thereby being
purchased, as designated in the Notice of Exercise (the “Aggregate Exercise Price”) by wire transfer or cashier’s
check drawn on a United States bank or pursuant to the cashless exercise procedure specified in Section 2(c) below. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the
Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case,
the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date the final Notice
of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number
of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder
in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of
Exercise Form within two (2) Business Days of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount
stated on the face hereof.

 

    1 

     

    

 

b)                 
Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $0.0994, subject to
adjustment hereunder (the “Exercise Price”).

 

c)                 
Cashless Exercise. In lieu of payment of the Aggregate Exercise Price, at the option of the Holder, this Warrant
may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall
be entitled to receive a certificate for the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by
(A), where:

 

		(A) = 	the
                                         VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise
                                         this Warrant by means of a “cashless exercise,” as set forth in the applicable
                                         Notice of Exercise;

 

		(B) = 	the
                                         Exercise Price of this Warrant, as adjusted hereunder; and

 

		(X) = 	the
                                         number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance
                                         with the terms of this Warrant if such exercise were by means of a cash exercise rather
                                         than a cashless exercise.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based
on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time), (b)  if the Common Stock is not then
listed or quoted for trading on a Trading Market and if prices for the Common Stock are then reported in the “Pink Sheets”
published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the
most recent bid price per share of the Common Stock so reported, or (c) in all other cases, the fair market value of a share
of Common Stock as determined by an independent appraiser selected in good faith by the Company and reasonably acceptable to the
Holders of a majority in interest of the Securities then outstanding, the fees and expenses of which shall be paid by the Company.

 

    2 

     

    

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE MKT, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global Select Market, the
New York Stock Exchange, the OTCQB or the OTC Bulletin Board (or any successors to any of the foregoing).

 

 

		d)	Mechanics
                                         of Exercise.

 

i.           
Delivery of Certificates Upon Exercise. Certificates for shares purchased hereunder shall be transmitted by the
Transfer Agent to the Holder by crediting the account of the Holder’s prime broker with the Depository Trust Company through
its Deposit Withdrawal Agent Commission (“DWAC”) system if the Company is then a participant in such system
and the Holder is not an affiliate of the Company and either (A) there is an effective Registration Statement permitting the resale
of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise at least six months following the
Initial Exercise Date, and otherwise by physical delivery to the address specified by the Holder in the Notice of Exercise by
the date that is three (3) Trading Days after the latest of (A) the delivery to the Company of the Notice of Exercise Form, (B)
surrender of this Warrant (if required) and (C) payment of the Aggregate Exercise Price as set forth above (including by cashless
exercise). This Warrant shall be deemed to have been exercised on the first date on which all of the foregoing have been delivered
to the Company. The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named
therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been
exercised, with payment to the Company of the Exercise Price (or by cashless exercise) and all taxes required to be paid by the
Holder, if any, pursuant to Section 2(d)(iv) prior to the issuance of such shares, having been paid.

 

ii.           
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at
the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates
representing Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant
Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

    3 

     

    

 

iii.           
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon
the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal
to such fraction multiplied by the Exercise Price or round up to the next whole share.

 

iv.           
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder
for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and
expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names
as may be directed by the Holder; provided, however, that in the event certificates for Warrant Shares are to be
issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment
Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient
to reimburse it for any transfer tax incidental thereto.

 

v.           
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely
exercise of this Warrant, pursuant to the terms hereof.

 

	Section 3.	                 
    Certain Adjustments.

 

a)                 
Stock Dividends and Splits. In case of: (i) any subdivision or combination of the Common Stock or (ii) any declaration
or payment, without consideration, of any dividend on the Common Stock payable in shares of the Company’s capital stock
or in any right to acquire shares of its capital stock without consideration, the number of shares of Common Stock or other security
issuable upon exercise hereof shall be proportionately increased or decreased, as appropriate, and the Exercise Price shall be
proportionately adjusted such that the Aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to
receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision
or combination.

 

    4 

     

    

 

b)                 
Reclassification. In case of any reclassification of or similar change in the Common Stock, the Company shall execute
a new Warrant having substantially similar terms and providing that the holder of this Warrant shall have the right to exercise
such new Warrant for the kind and number of shares of stock, other securities, money or property receivable upon such reclassification
or change by holders of the Common Stock.

 

c)                 
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Company with or into another Person and the Company
is not the surviving corporation, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any,
direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant
to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property
and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property, (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme
of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock
(not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated
with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental
Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each
Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction,
at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of
shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any
additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental
Transaction. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply
to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are
given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the “Successor Entity”) to assume all of the obligations of the Company under this Warrant in accordance with
the provisions of this Section 3(e) prior to such Fundamental Transaction and shall, at the option of the holder of this Warrant,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such
Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares
of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose
of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which
is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor
Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor
Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this
Warrant with the same effect as if such Successor Entity had been named as the Company herein. “Person” shall
mean an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

    5 

     

    

 

d)             Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

		e)	Notice
                                         to Holder.

 

i.           
Adjustment. Whenever the Exercise Price or the number of shares of Common Stock issuable upon exercise is adjusted
pursuant to any provision of this Section 3, the Company shall promptly mail to the Holder a notice setting forth the Exercise
Price after such adjustment and setting forth a brief statement of the facts requiring such adjustment.

 

ii.           
Notice to Allow Exercise by Holder. If during the term during which this Warrant may be exercised (A) the Company
shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special
nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders
of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights,
(D) the approval of any stockholders of the Company shall be required in connection with any consolidation or merger to which
the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share
exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the
voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be mailed to the Holder at its last address as it shall appear upon the Warrant Register (as defined below) of
the Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating
(x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such consolidation, merger, sale,
transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the
Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice
or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified
in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding
the Company or any of the subsidiaries of the Company, the Company shall simultaneously file such notice with the SEC pursuant
to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the
date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

 

    6 

     

    

 

	Section 4.	                 
    Transfer of Warrant.

  

a)                 
Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section
4(d) hereof and to the provisions of Section 5 of the Purchase Agreement, this Warrant and all rights hereunder (including, without
limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office
of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form of the Assignment
Form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable
upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a
new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified
in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

b)                 
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid
office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the initial issuance date set forth on the first page of this Warrant and shall be identical with this Warrant except as to the
number of Warrant Shares issuable pursuant thereto.

 

    7 

     

    

 

c)                 
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

d)                
Transfer Restrictions. If, at the time of the surrender of this
Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant
to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii)
eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule
144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the
case may be, comply with the provisions of Section 9(h) of the Purchase Agreement.

 

e)                 
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring
this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and
not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act
or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.

 

	Section 5.	                 
    Miscellaneous.

 

a)                 
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).

 

b)                 
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating
to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which,
in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or
stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated
as of such cancellation, in lieu of such Warrant or stock certificate.

 

    8 

     

    

 

c)                 
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised
on the next succeeding Business Day.

 

d)                
Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from
its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon
the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall
constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the
necessary certificates for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take
all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation
of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The
Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant
will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith,
be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company
in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

 

e)                 
No Impairment. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action,
including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the
taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against
impairment.

 

f)                  
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant
shall be determined in accordance with the provisions of the Purchase Agreement.

 

g)                 
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part
of Holder shall operate as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies. If the Company
willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder,
the Company shall pay to Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited
to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by Holder in collecting any amounts due
pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

    9 

     

    

 

h)                 
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the
Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

 

i)                   
Limitation of Liability. No provision hereof and no enumeration herein of the rights or privileges of Holder, shall
give rise to any liability of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such
liability is asserted by the Company or by creditors of the Company.

 

j)                   
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to seek specific performance of its rights under this Warrant. The Company agrees that monetary damages
would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby
agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)                 
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors
and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to
time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

l)                   
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the
Company and the Holder.

 

m)               
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)                 
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose,
be deemed a part of this Warrant.

 

********************

 

(Signature
Pages Follow)

 

    10 

     

    

 

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.

 

 

	 	Interleukin
                    Genetics, Inc.

	 	 
	 	 	 
	 	By:  	 
	 	 	

        Name: Mark B. Carbeau

        Title: Chief Executive Officer

 

    11 

     

    

 

NOTICE
OF EXERCISE

 

To:Interleukin
Genetics, Inc.

 

(1)  
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached
Warrant (only if exercised in full), and tenders herewith payment of the exercise price for said Warrant Shares in full, together
with all applicable transfer taxes, if any.

 

(2)  
Payment shall take the form of (check applicable box):

 

 ̈  in
lawful money of the United States; or

 

 ̈  the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula
set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant
to the cashless exercise procedure set forth in subsection 2(c).

 

(3)  
Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other
name as is specified below:

 

_______________________________

 

 

The Warrant
Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

_______________________________

 

_______________________________

 

_______________________________

 

 

[SIGNATURE
OF HOLDER]

 

	Name
    of Holder:   	 

	Signature
    of Authorized Signatory of Holder:   	 

	Name
    of Authorized Signatory:   	 

	Title
    of Authorized Signatory:   	 

	Date:  	 

 

     

     

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

 

 

FOR
VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

 

 

	 	  whose address
    is
	 	 
	.
	 
	 
	 
	 

 

		Dated:
    ______________, _______

 

 

	Holder’s
    Signature:    	 
	 	 
	Holder’s
    Address:    	 
	 	 
	 	 

 

 

	Signature Guaranteed:  	 
	 	 

 

 

NOTE: The signature
to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement
or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary
or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.Exhibit
10.1

EXECUTION
COPY

 

 

 

 

 

 

 SECURITIES
PURCHASE AGREEMENT

 

by and between

 

Interleukin Genetics, Inc.

 

and

 

The Purchasers Identified on Schedule
I Hereto

 

 

 

July 29, 2016

 

 

 

 

 

 

 

 

     

     

    

 

Table
of Contents

 

	 	 	 	Page
	 	 	 	 
	1.	PURCHASE AND SALE	1
	 	(a)	Authorization of Shares	1
	 	(b)	Purchase of Shares and Warrants	1
	2.	CLOSING	1
	 	(a)	The Closing	1
	 	(b)	Form of Payment	2
	 	(c)	Conditions to the Purchaser’s Obligation to Purchase on the Closing Date	2
	 	(d)	Conditions to the Company’s Obligation to Issue and Sell on the Closing Date	3
	3.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY	4
	 	(a)	Organization and Qualification	4
	 	(b)	Subsidiaries	4
	 	(c)	Authorization; Enforcement; Validity	4
	 	(d)	Capitalization	5
	 	(e)	Issuance of Shares	5
	 	(f)	No Conflicts	6
	 	(g)	No Violation or Default	6
	 	(h)	SEC Documents	6
	 	(i)	Financial Statements	7
	 	(j)	No Material Adverse Change	7
	 	(k)	Independent Accountants	7
	 	(l)	Title to Intellectual Property	8
	 	(m)	Licenses and Permits; Compliance with Law	8
	 	(n)	Insurance	8
	 	(o)	Related Party Transactions	9
	 	(p)	Environmental Matters	9
	 	(q)	Tax Matters	9

 

    -i-

     

    

 

Table of Contents

(continued)

 

	 	 	 	Page
	 	 	 	 
	 	(r)	Employees	9
	 	(s)	Internal Control over Financial Reporting	10
	 	(t)	Disclosure Controls and Procedures	10
	 	(u)	Sarbanes-Oxley Compliance	10
	 	(v)	Absence of Litigation	10
	 	(w)	Investment Company Act	11
	 	(x)	No Market Manipulation	11
	 	(y)	Foreign Corrupt Practices	11
	 	(z)	Brokers	11
	 	(aa)	Regulation	11
	4.	PURCHASERS’ REPRESENTATIONS AND WARRANTIES	12
	 	(a)	Transfer or Resale	12
	 	(b)	Investment Purpose	12
	 	(c)	General Solicitation	12
	 	(d)	Information	12
	 	(e)	Reliance on Exemptions	12
	 	(f)	No Governmental Review	13
	 	(g)	Authorization; Enforcement; Validity	13
	 	(h)	No Conflicts	13
	5.	RESTRICTIONS ON TRANSFER	13
	 	(a)	Resales	13
	 	(b)	Rule 144	13
	 	(c)	Legends	14
	 	(d)	Legend Removal	14
	6.	BOARD COMPOSITION	15
	 	(a)	Board Composition; Appointment of Director Designees	15
	 	(b)	Nominations of Director Designees	15
	 	(c)	Successor Director Designees	15

 

 

    -ii-

     

    

 

 Table of Contents

(continued)

 

	 	 	 	Page
	 	 	 	 
	 	(d)	Indemnification Agreements	16
	 	(e)	Committees of the Board of Directors	16
	 	(f)	Amendment of this Section 6	16
	 	(g)	Board Observer Rights	16
	7.	OTHER AGREEMENTS AND COVENANTS	17
	 	(a)	National Market Listing	17
	 	(b)	Use of Proceeds	17
	 	(c)	Form D; Blue Sky Filings	17
	 	(d)	Reservation of Shares	17
	 	(e)	Exchange Act Filings	17
	 	(f)	Integration	17
	 	(g)	Expenses	18
	 	(h)	Purchaser/Director Designee Exchange Act Filings	18
	8.	PUBLIC STATEMENTS	18
	9.	MISCELLANEOUS	18
	 	(a)	Governing Law	18
	 	(b)	Entire Agreement	19
	 	(c)	Amendments and Waivers	19
	 	(d)	Notices	19
	 	(e)	No Strict Construction	20
	 	(f)	Further Assurances	20
	 	(g)	Severability	20
	 	(h)	Successors and Assigns	20
	 	(i)	Survival	20
	 	(j)	No Third-Party Beneficiaries	21
	 	(k)	Replacement of Securities	21
	 	(l)	Independent Nature of Purchasers’ Obligations and Rights	21
	 	(m)	Business Day	21

 

    -iii-

     

    

 

Table of Contents

(continued)

 

	 	 	 	Page
	 	 	 	 
	 	(n)	Headings	21
	 	(o)	Execution	21

 

 

SCHEDULES

Schedule I – List of Purchasers

 

EXHIBITS

Exhibit A – Form of Warrant

 

Exhibit B – Registration Rights Agreement

 

 

    -iv-

     

    

 

SECURITIES
PURCHASE AGREEMENT

 

This Securities Purchase Agreement (this
“Agreement”) dated as of July 29, 2016 is made by and between Interleukin Genetics, Inc., a Delaware corporation,
(the “Company”), and each purchaser identified on Schedule I hereto (each a “Purchaser”),
and together, the “Purchasers”). 

 

RECITALS

 

In accordance with the terms and conditions
of this Agreement and pursuant to exemptions from registration under the Securities Act of 1933, as amended (the “Securities
Act”), the Company has agreed to issue and sell, and each Purchaser has agreed, severally and not jointly, to purchase
a number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and
a warrant to purchase a number of shares of Common Stock (the “Warrant”, and together with all such warrants
being issued to Purchasers under this Agreement, the “Warrants”), each as set forth opposite such Purchaser’s
name on Schedule I to this Agreement.

 

NOW THEREFORE, in consideration of the promises
and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company and each Purchaser hereby agree as follows:

 

		1.	PURCHASE AND SALE

 

(a)         
Authorization of Shares and Warrants. The Company has authorized (i) the sale and issuance to the Purchasers
of the shares of Common Stock, (ii) the sale and issuance to the Purchasers of the Warrants, and (iii) the issuance of shares
of Common Stock to be issued upon exercise of the Warrants (the “Warrant Shares”).

 

(b)        
Purchase of Shares and Warrants. At the Closing (as defined below), the Company shall issue and sell to each Purchaser,
and each Purchaser shall, severally and not jointly, purchase from the Company, upon the terms and subject to the conditions set
forth in this Agreement, (i) the number of shares of Common Stock set forth opposite such Purchaser’s name on Schedule
I to this Agreement (the “Shares”) and (ii) a Warrant to purchase the number of shares of Common Stock set
forth opposite such Purchaser’s name on Schedule I to this Agreement, for an aggregate purchase price as set forth
opposite such Purchaser’s name on Schedule I to this Agreement (the “Purchase Price”), based on
a purchase price per Share of $0.0994 (the “Per Share Purchase Price”).

 

		2.	CLOSING

 

(a)         
The Closing. The date and time of the Closing of the purchase and sale of the Shares and the Warrants (the “Closing”)
shall occur on July 29, 2016 at 12:00 p.m. Boston time, at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.,
One Financial Center, Boston, Massachusetts, 02111 (subject to the satisfaction or waiver of the conditions set forth in Subsections
(c) and (d) of this Section 2), or at such other location, date and time as may be agreed upon between the Company and the Purchasers
(the “Closing Date”).

 

    -1- 

     

    

 

(b)        
Form of Payment. On the Closing Date, each Purchaser shall pay the Company the Purchase Price for the Shares and
the Warrant to be issued and sold to such Purchaser on such Closing Date, by wire transfer of immediately available funds in accordance
with the Company’s written wire instructions previously provided to the Purchasers, and the Company shall deliver to each
Purchaser the original certificate or certificates representing the Shares and the original Warrant, duly executed on behalf of
the Company and registered in the name of such Purchaser.

 

(c)         
Conditions to the Purchaser’s Obligation to Purchase on the Closing Date. Each Purchaser’s obligation
to purchase the Shares and the Warrant at the Closing shall be subject to the satisfaction, on or before the Closing Date, of each
of the following conditions, provided that these conditions are for the Purchaser’s sole benefit and may be waived by such
Purchaser at any time in its sole discretion:

 

		(i)	receipt of a copy of this Agreement executed by the Company;

 

		(ii)	evidence of irrevocable instructions from the Company to the transfer agent for the Common Stock with respect to the issuance
and delivery of one or more certificates representing the Shares;

 

		(iii)	receipt of the Warrant in the form attached as Exhibit A;

 

		(iv)	all actions required by the Board of Directors of the Company (the “Board”) to effect the provisions of
Section 6 of this Agreement with respect to the composition of the Board following the Closing shall have been taken;

 

		(v)	all consents, approvals and waivers required for the consummation of the transactions contemplated hereby shall have been obtained;

 

		(vi)	the Company shall have delivered to the Purchasers a Compliance Certificate, executed by the Chief Executive Officer of the
Company, dated as of the Closing Date, to the effect that the conditions specified in subsections (v), (viii), and (ix) of
this Section 2(c) have been satisfied;

 

		(vii)	the Company shall have delivered to the Purchasers a certificate of its Secretary certifying as to (A) the resolutions
of the Board approving this Agreement and the transactions contemplated hereby, including the actions required by the Company pursuant
to this Section 2(c); and (B) good standing certificates (including tax good standing) with respect to the Company from
the applicable authority(ies) in Delaware and any other jurisdiction in which the Company is qualified to do business dated a recent
date before the Closing;

 

		(viii)	the representations and warranties of the Company in this Agreement shall be true, correct and complete as of the Closing Date
(except for representations and warranties that speak as of a specific date, which shall be true, correct and complete as of such
date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and
conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing;

 

    -2- 

     

    

 

		(ix)	no temporary restraining order, preliminary or permanent injunction or other order or decree, and no other legal restraint
or prohibition, shall exist which questions the validity of this Agreement or the right of the Company or any Purchaser, as the
case may be, to enter into this Agreement or prevents or could reasonably be expected to prevent the consummation of the transactions
contemplated by this Agreement, nor shall any litigation or court or administrative proceeding have been commenced or threatened
with respect to the foregoing;

 

		(x)	the Company shall have executed and delivered the Registration Rights Agreement in substantially the form attached as Exhibit B
(the “Registration Rights Agreement”);

 

		(xi)	delivery of a legal opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, Company counsel, in form and substance reasonably
satisfactory to the Purchasers; and

 

		(xii)	receipt of such other information, certificates and documents as the Purchasers may reasonably request.

 

(d)        
Conditions to the Company’s Obligation to Issue and Sell on the Closing Date. The Company’s obligation
to issue and sell the Shares and the Warrant at the Closing shall be subject to the satisfaction, on or before the Closing Date,
of each of the following conditions, provided that these conditions are for the Company’s sole benefit and may be waived
by the Company at any time in its sole discretion:

 

		(i)	receipt of a copy of this Agreement executed by each Purchaser;

 

		(ii)	receipt of the Purchase Price from each Purchaser;

 

		(iii)	the representations and warranties of each Purchaser in this Agreement shall be true, correct and complete as of the date of
this Agreement and as of the Closing Date (except for representations and warranties that speak as of a specific date, which shall
be true, correct and complete as of such date) and each Purchaser shall have performed, satisfied and complied with in all material
respects the covenants, agreements and conditions of such Purchaser to be performed, satisfied or complied with by it under this
Agreement at or prior to the Closing Date; and

 

		(iv)	no temporary restraining order, preliminary or permanent injunction or other order or decree, and no other legal restraint
or prohibition shall exist which questions the validity of this Agreement or the right of the Company or any Purchaser, as the
case may be, to enter into this Agreement or prevents or could reasonably be expected to prevent the consummation of the transactions
contemplated by this Agreement, nor shall any litigation or court or administrative proceeding have been commenced or threatened
with respect to the foregoing.

 

    -3- 

     

    

 

		3.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The Company represents and warrants to each
Purchaser, subject to such exceptions as are set forth in the SEC Documents (as defined below) (other than (x) those sections of
the SEC Documents entitled or captioned “Risk Factors,” (y) any disclosure of risks included in any forward-looking
statements disclaimer or other statements that are similarly non-specific and are predictive or forward looking in nature and (z)
specific disclosures contained in those documents which are filed as exhibits to the SEC Documents), provided that the relevance
of such exceptions to the representations and warranties is reasonably apparent, as follows:

 

(a)         
Organization and Qualification. The Company is a corporation, duly organized, validly existing and in good standing
under the laws of the State of Delaware, and has the requisite corporate power and authority to own its properties and to carry
on its business as now being conducted and as described in the SEC Documents. Copies of the Company’s Restated Certificate
of Incorporation, as amended (the “Charter”), and Amended and Restated Bylaws of the Company, as amended (the
“Bylaws”), and in each case, all amendments thereto, have been filed as exhibits to the Company’s SEC
Documents and have not been further modified, and except as otherwise may be required by the transactions contemplated hereby,
the Company has no present intention to modify the Charter and Bylaws. The Company is duly qualified as a foreign corporation to
do business, and is in good standing, in every jurisdiction in which its ownership of property or the nature of the business conducted
and proposed to be conducted by it makes such qualification necessary, except where the failure to be so qualified or in good standing
would not, individually or in the aggregate, have or reasonably be expected to result in a material adverse effect on (i) the condition
(financial or otherwise), prospects, earnings, assets, results of operations, business or properties of the Company, whether or
not arising from transactions in the ordinary course of business or (ii) the ability of the Company to consummate the transactions
contemplated by this Agreement (“Material Adverse Effect”).

 

		(b)	Subsidiaries. The Company has no subsidiaries.

 

(c)         
Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and
perform its obligations under this Agreement, the Registration Rights Agreement and each of the other agreements entered into by
the parties hereto in connection with transactions contemplated by this Agreement (collectively, the “Transaction Documents”)
and to issue the Shares and the Warrants in accordance with the terms hereof and thereof. The execution and delivery of the Transaction
Documents by the Company and the consummation and performance by the Company of the transactions contemplated hereby and thereby,
including, without limitation, the issuance of the Shares, Warrants and the Warrant Shares (collectively, the “Securities”),
have been duly authorized by all requisite corporate action. The Transaction Documents have been duly executed and delivered by
the Company. The Transaction Documents constitute the valid and binding obligations of the Company enforceable against the Company
in accordance with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’
rights and remedies.

 

    -4- 

     

    

 

(d)        
Capitalization. As of the date of this Agreement, the authorized capital stock of the Company consists of (i) 450,000,000
shares of Common Stock and (ii) 6,000,000 shares of undesignated preferred stock, $0.001 par value per share. As of the date of
this Agreement and prior to the issuance of the Shares and Warrants under this Agreement, (i) 173,029,840 shares of Common Stock
are issued and outstanding; (ii) 22,062,770 shares of Common Stock are duly reserved for future issuance pursuant to outstanding
stock options; (iii) 88,301,079 shares of Common Stock are duly reserved for future issuance pursuant to outstanding warrants;
(iv) 30,044,509 shares of Common Stock are duly reserved for future issuance pursuant to the Company’s stock plans;
and (v) 157,454 shares of Common Stock are duly reserved for future issuance pursuant to the Company’s employee stock
purchase plan. All of the issued shares of capital stock of the Company have been duly and validly authorized and issued, are fully
paid and non-assessable, and have been issued in compliance with federal and state securities laws. Except as set forth above,
(i) no shares of the Company’s capital stock are subject to preemptive rights or any other similar rights or any liens or
encumbrances; (ii) there are no outstanding options, warrants, rights to subscribe to, calls or commitments relating to, or securities
or rights convertible into, any shares of capital stock of the Company, or contracts, commitments, understandings or arrangements
by which the Company is or may become bound to issue additional shares of capital stock of the Company or options, warrants, rights
to subscribe to, calls or commitments relating to, or securities or rights convertible into, any shares of capital stock of the
Company. The Company has no knowledge of any voting agreements, buy-sell agreements, option or right of first purchase agreements
or other agreements of any kind among any of the security holders of the Company relating to the securities of the Company held
by them. Other than (i) pursuant to the Registration Rights Agreement, (ii) with respect to the shares of Common Stock issuable
upon exercise of the warrant to be issued pursuant to that certain Venture Loan and Security Agreement, dated December 23, 2014,
by and between Interleukin and Horizon, (iii) except as set forth in that certain Registration Rights Agreement, dated May 17,
2013, between the Company and the purchasers signatory thereto, and (iv) except as set forth in that certain Registration Rights
Agreement, dated December 23, 2014, between the Company and the purchasers signatory thereto, the Company has not granted any person
the right to require the Company to register any securities of the Company under the Securities Act, whether on a demand basis
or in connection with the registration of securities of the Company for its own account or for the account of any other person.

 

(e)         
Issuance of Shares. The Shares and the Warrant Shares have been duly and validly reserved for issuance. The Shares
and the Warrant Shares are duly authorized and, upon issuance in accordance with the terms hereof and the Warrants, will be (A)
validly issued, fully paid and non-assessable and (B) free from all taxes, liens and charges in the United States of America with
respect to the issuance thereof, other than any liens or encumbrances created by or imposed by the Purchaser, and not subject to
preemptive, registration, right of first refusal or other similar rights of stockholders of the Company. Except for the filing
of any notice prior or subsequent to the Closing that may be required under applicable state and/or federal securities laws (or
comparable laws of any other jurisdiction), no authorization, consent, approval, license, exemption of or filing or registration
with any court or governmental department, commission, board, bureau, agency, instrumentality or other third party, is or will
be necessary for, or in connection with, the execution and delivery by the Company of this Agreement, for the offer, issue, sale,
execution or delivery of the Shares and Warrants, or for the performance by the Company of its obligations under this Agreement.
The Company has reserved from its duly authorized capital stock the Shares and the Warrant Shares.

 

    -5- 

     

    

 

(f)         
No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby do not and will not (i) result in a breach or violation of the
Company’s Charter or Bylaws; (ii) conflict with, or constitute a default (or an event which with notice or lapse of time
or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of,
or incremental, additional or varied rights under, any agreement, indenture, or other instrument, obligation or understanding to
which the Company is a party; (iii) result in a violation of any statute, law, rule, regulation, order, judgment or decree (including
federal and state securities laws) applicable to the Company; or (iv) result in the imposition of a mortgage, pledge, security
interest, encumbrance, charge or other lien on any asset of the Company.

 

(g)        
No Violation or Default. The Company is not (i) in violation of its Charter or Bylaws; (ii) in default (or subject
to an event which with notice or lapse of time or both would become a default) under any agreement, indenture or instrument to
which the Company is a party; or (iii) in violation of any law, rule, regulation, order, judgment or decree applicable to the Company;
except for such violations or defaults, as described in clauses (ii) or (iii) of this sentence as would not, individually or in
the aggregate, have or result in a Material Adverse Effect.

 

(h)        
SEC Documents. The Company has filed all reports, schedules, forms, statements, exhibits (including certifications
of the Company’s principal executive and financial officers pursuant to Section 302 and 906 of Sarbanes-Oxley (as defined
below)) and other documents required to be filed by it with the U.S. Securities and Exchange Commission (“SEC”)
pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
since January 1, 2015 (all of the foregoing filed prior to or on the date hereof, or prior to the Closing Date, and all exhibits
included therein and financial statements and schedules thereto and documents incorporated by reference therein being referred
to in this Agreement as the “SEC Documents”). As of the date of filing of each such SEC Document, such SEC Document,
as it may have been subsequently amended by filings made by the Company with the SEC prior to the date hereof, complied in all
material respects with the requirements of the Exchange Act and the rules and regulations of the SEC promulgated thereunder applicable
to such SEC Document. None of the SEC Documents, as of the date filed and as they may have been subsequently amended by filings
made by the Company with the SEC prior to the date hereof, contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading.

 

    -6- 

     

    

 

(i)          
Financial Statements. The financial statements and the related notes thereto of the Company included or incorporated
by reference in the SEC Documents comply in all material respects with the applicable requirements of the Exchange Act and present
fairly and accurately in all material respects the financial position of the Company as of the dates indicated and the results
of operations and the changes in cash flows for the periods specified. Such financial statements have been prepared in conformity
with United States generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout
the periods covered thereby, except as specifically stated therein, and the supporting schedules included or incorporated by reference
in the SEC Documents present fairly the information required to be stated therein. The Company does not have any material liability
or obligation of any nature, whether or not accrued, contingent or otherwise that would be required by GAAP to be disclosed on
a balance sheet of the Company or in the notes thereto. The Company has not created any entities or entered into any transactions
or created any liabilities or obligations of any nature, whether or not accrued, contingent or otherwise, for the purpose of avoiding
disclosure required by GAAP.

 

(j)          
No Material Adverse Change. Since the date of the most recent financial statements of the Company included or incorporated
by reference in the SEC Documents, except as disclosed in the SEC Documents and as contemplated by this Agreement, (i) there
has not been any change in the capital stock (other than pursuant to the Company's stock plans pursuant to the Company's existing
employee stock purchase plan (any such issuances, whenever issued or granted, being collectively “Employee Equity Transactions”),
pursuant to the conversion or exercise of outstanding securities that are convertible into or exercisable for Common Stock, or
pursuant to publicly disclosed equity or debt financings) or long-term debt of the Company, or any dividend or distribution of
any kind declared, set aside for payment, paid or made by the Company on any class of capital stock; (ii) the Company has not entered
into any transaction or agreement that is material to the Company taken as a whole or incurred any liability or obligation, direct
or contingent, that is material to the Company and, except as contemplated by this agreement, has not made any material change
or amendment to a material contract or arrangement by which the Company or any of its assets or properties is bound or subject;
(iii) the Company has not sustained any material loss or interference with its business from fire, explosion, flood or other calamity,
whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator
or governmental or regulatory authority; and (iv) there has not been the occurrence of any Material Adverse Effect.

 

(k)        
Independent Accountants. Grant Thornton LLP, who have certified certain financial statements of the Company, have
advised the Company that they are, and to the Company’s knowledge they are, independent registered public accountants with
respect to the Company as required by the Securities Act. Except as pre-approved in accordance with the requirements set forth
in Section 10A of the Exchange Act, to the Company’s knowledge, Grant Thornton LLP has not engaged in any “prohibited
activities” (as defined in Section 10A of the Exchange Act) on behalf of the Company.

 

    -7- 

     

    

 

(l)          
Title to Intellectual Property. The Company owns or possesses adequate rights to use all patents, patent applications,
trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions,
know-how and all other intellectual property rights (including trade secrets and other unpatented or unpatentable proprietary or
confidential compounds, genes, information, systems or procedures) (collectively, the “Intellectual Property”),
used in or necessary for the conduct of the Company’s business as now, or as contemplated to be, conducted. Except as set
forth in the SEC Documents, (i) there are no rights of third parties to any such Intellectual Property except through licensing
or cross-licensing agreements; (ii) to the Company’s knowledge, there is no infringement by third parties of any Intellectual
Property to which the Company can assert a claim of infringement; (iii) there is no pending or, to the Company’s knowledge,
threatened action, suit, proceeding or claim by others challenging the Company’s ownership of or licensing rights in or to
any such Intellectual Property; (iv) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding
or claim by others challenging the validity or scope of any such Intellectual Property, other than ordinary patent, trademark,
service mark and copyright prosecution disclosed in the SEC Documents; (v) there is no pending or, to the Company’s
knowledge, threatened action, suit, proceeding or claim by others that the Company infringes or otherwise violates any Intellectual
Property of others, and the Company is unaware of any reasonable basis for any such claim; (vi) the Company has not been and
will not be required to utilize any inventions, trade secrets or proprietary information of any of its employees made prior to
their employment by the Company; (vii) the Company has taken all steps required to perfect its ownership of and interest in
its Intellectual Property; and (viii) the Company has taken reasonable security measures to protect the secrecy, confidentiality
and value of all of its Intellectual Property.

 

(m)      
Licenses and Permits; Compliance with Law. The Company possesses all licenses, certificates, permits and other authorizations
issued by, and has made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory
authorities, that are necessary for the ownership or lease of its properties and assets or the conduct of its business as conducted
or as contemplated to be conducted. The Company has not received notice of any revocation or modification of any such license,
certificate, permit or authorization, or of any proceeding relating to any such revocation or modification, or has any reason to
believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course. The Company has
complied in all material respects with and is not in default or violation in any material respect of, and is not, to the Company’s
knowledge, under investigation with respect to or has not been, to the knowledge of the Company, threatened to be charged with
or given notice of any violation of, any applicable federal, state, local or foreign law, statute, ordinance, license, rule, regulation,
policy or guideline, order, demand, writ, injunction, decree or judgment of any federal, state, local or foreign governmental or
regulatory authority. Except for statutory or regulatory restrictions of general application, no federal, state, local or foreign
governmental or regulatory authority has placed any material restriction on the business or properties of the Company.

 

(n)        
Insurance. The Company maintains insurance of the types and in the amounts that the Company reasonably believes are
adequate for its businesses and consistent with insurance coverage maintained by similar companies in similar businesses, including,
but not limited to, insurance covering real and personal property owned or leased by the Company against theft, damage, destruction,
acts of vandalism, insurance covering the acts and omissions of directors and officers, and insurance covering all other risks
customarily insured against by similarly situated companies, all of which insurance is in full force and effect. The Company has
not received any written notice that the Company will not be able to renew its existing insurance coverage as and when such coverage
expires.

 

    -8- 

     

    

 

(o)        
Related Party Transactions. Except as contemplated by this Agreement, none of the officers or directors of the Company
and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company
(other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing
for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments
to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director,
or any such employee has a substantial interest or is an officer, director, trustee or partner, in each case in excess of $120,000
other than (i) for payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on
behalf of the Company and (iii) for other employee benefits, including stock option agreements under any stock option plan of the
Company.

 

(p)        
Environmental Matters. The Company is in compliance with all foreign, federal, state and local rules, laws and regulations
relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection of health and safety
or the environment which are applicable to their businesses. To the Company’s knowledge, there has been no storage, generation,
transportation, handling, treatment, disposal, discharge, emission, or other release of any kind of toxic or other wastes or other
hazardous substances by, due to, or caused by the Company (or, to the Company’s knowledge, any other entity for whose acts
or omissions the Company is or may be liable) upon any of the property now or previously owned or leased by the Company, or upon
any other property, in violation of any statute or any ordinance, rule, regulation, order, judgment, decree or permit or which
would, under any statute or any ordinance, rule (including rule of common law), regulation, order, judgment, decree or permit,
give rise to any liability. There has been no disposal, discharge, emission or other release of any kind onto such property or
into the environment surrounding such property of any toxic or other wastes or other hazardous substances with respect to which
the Company has knowledge.

 

(q)        
Tax Matters. The Company (i) has timely filed all necessary federal, state, local and foreign income and franchise
tax returns or has requested extensions thereof, (ii) has paid all federal state, local and foreign taxes due and payable for which
it is liable, except for any such taxes currently being contested in good faith, and (iii) does not have any tax deficiency or
claims outstanding or assessed or, to the best of the Company’s knowledge, proposed against it. All material taxes and other
assessments and levies that the Company is required to withhold or to collect for payment have been duly withheld and collected
and paid to the proper government entity or third party when due. There are no tax liens or claims pending or, to the Company’s
knowledge, threatened against the Company or any of its respective assets or property. Except as set forth in the SEC Documents,
there are no outstanding tax sharing agreements or other such arrangements between the Company and any other Person.

 

(r)          
Employees. All current and former employees of the Company have executed and delivered a confidential information
and inventions assignment agreement (a “CIIA”) to the Company. All current and former consultants of the Company
that had access to confidential or proprietary information of the Company have executed and delivered a CIIA to the Company or
other form of written contract or agreement with the Company that requires such consultants to maintain the confidentiality of
such information and assigns to the Company all rights to any inventions, improvements, discoveries or information relating to
the business of the Company. The Company is not aware that any executive officer of the Company has plans to terminate his or her
employment relationship with the Company. The Company has complied in all material respects with all applicable laws relating to
wages, hours, equal opportunity, collective bargaining, workers’ compensation insurance and the payment of social security
and other taxes. None of the employees of the Company is represented by any labor union, and there is no labor strike or other
labor trouble pending or, to the Company’s knowledge, threatened with respect to the Company. To the Company’s knowledge,
no employee of the Company is obligated under any contract or subject to any judgment, decree or administrative order that would
conflict or interfere with (i) the performance of the employee’s duties as an employee, director or officer of the Company,
or (ii) the Company’s business as conducted or proposed to be conducted.

 

    -9- 

     

    

 

(s)         
Internal Control over Financial Reporting. The Company maintains a system of internal control over financial reporting
(as such is defined in Rule 13a-15(f) of the Exchange Act) that complies with the requirements of the Exchange Act and has been
designed by the Company’s principal executive officer and principal financial officer, or under their supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with GAAP. The Company does not have any material weaknesses in its internal control over financial reporting.
Since the date of the latest audited financial statements included in the SEC Documents, there has been no change in the Company’s
internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s
internal control over financial reporting.

 

(t)          
Disclosure Controls and Procedures. The Company maintains disclosure controls and procedures (as such term is defined
in Rule 13a-15(e) of the Exchange Act) that comply with the requirements of the Exchange Act. Such disclosure controls and procedures
have been designed to ensure that material information relating to the Company is accumulated and communicated to the Company’s
management, including the Company’s principal executive officer and principal financial officer, by others within those entities.

 

(u)        
Sarbanes-Oxley Compliance. The Company and the Company’s directors and officers, in their capacities as such,
are in compliance with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection
therewith (“Sarbanes-Oxley”), including Section 402 related to loans and Sections 302 and 906 related to certifications,
and neither the Company nor any of its officers has received notice from any governmental entity questioning or challenging the
accuracy, completeness, content, form or manner of filing or submission of such certifications. The Company has no reasonable basis
to believe that it will not continue to be in compliance with Sarbanes-Oxley as in effect on the Closing Date (including, without
limitation, the requirements of Section 404 thereof).

 

(v)        
Absence of Litigation. There is no action, suit, proceeding, inquiry or investigation before or by any court, public
board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company, threatened in writing
against the Company which (i) adversely affects or challenges the legality, validity or enforceability of this Agreement or
the Securities or (ii) would reasonably be expected to result in a Material Adverse Effect.

 

    -10- 

     

    

 

(w)      
Investment Company Act. The Company is not, nor, after giving effect to the sale of the Shares and the Warrants and
the application of the proceeds therefrom, will it become, an “investment company” within the meaning of the Investment
Company Act of 1940, as amended, and the rules and regulations of the SEC thereunder.

 

(x)        
No Market Manipulation. Neither the Company nor, to the knowledge of the Company, any of the Company’s directors,
officers, employees, agents or controlling persons have taken, directly or indirectly, any action designed, or that might reasonably
be expected, to cause or result in, under the Securities Act or otherwise, or that has constituted, stabilization or manipulation
of the price of the Common Stock.

 

(y)        
Foreign Corrupt Practices. Neither the Company nor, to the Company’s knowledge, any director, officer, agent,
employee or other person acting on behalf of the Company has, in the course of its actions for, or on behalf of, the Company, (i)
directly or indirectly, used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses
relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official
or employee from corporate funds; (iii) violated or is in violation of in any material respect any provision of the U.S. Foreign
Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other
unlawful payment to any foreign or domestic government official or employee.

 

(z)         
Brokers. Neither the Company nor any of the Company's officers, directors, employees or stockholders has employed
or engaged any broker or finder in connection with the transactions contemplated by this Agreement and no other fee or other compensation
is or will be due and owing to any broker, finder, underwriter, placement agent or similar person in connection with the transactions
contemplated by this Agreement.

 

(aa)     
Regulation. Assuming the accuracy of the representations and warranties made by the Purchasers in Section 4 of this
Agreement, the offer, issuance, sale and delivery of the Securities are or will be exempt from the registration requirements of
the Securities Act and the qualification or registration provisions of applicable state securities laws. Neither the Company nor
its authorized agents have taken or will take any action that would cause the loss of such exemption. Neither the Company nor any
person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D)
in connection with the offer or sale of any of the Securities. Neither the Company nor any of its affiliates, nor any person acting
on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any
security, under circumstances that would adversely affect reliance by the Company on Section 4(2) of the Securities Act for
the exemption from registration for the contemplated transactions under this Agreement or would require registration of the Shares
or the Common Shares under the Securities Act.

 

    -11- 

     

    

 

		4.	PURCHASERS’ REPRESENTATIONS AND WARRANTIES

 

Each Purchaser, for itself and for no other
Purchaser, hereby represents and warrants to the Company as follows:

 

(a)         
Transfer or Resale. The Purchaser understands that the Securities have not been registered under the Securities Act
or any state securities laws, and may not be offered for sale, sold, assigned or transferred without registration under the Securities
Act or an exemption therefrom and that, in the absence of an effective registration statement under the Securities Act, such Securities
may only be sold under certain circumstances as set forth in the Securities Act.

 

(b)        
Investment Purpose. The Purchaser is acquiring the Securities for its own account for investment only and not with
a view towards, or for resale in connection with, the public sale or distribution thereof. The Purchaser does not have any agreement
or understanding, directly or indirectly, with any person to distribute any of the Securities.

 

(c)         
General Solicitation. The Purchaser was contacted regarding the sale of the Securities by an authorized representative
of the Company or an agent of the Company with whom the Purchaser has a prior substantial pre-existing relationship and the Purchaser
is not purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities
published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any
other general solicitation or general advertisement.

 

(d)        
Information. The Purchaser (directly or through its advisors, if any) (i) has been furnished with or has had full
access to all of the publicly available information that it considers necessary or appropriate for deciding whether to purchase
the Securities, (ii) has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions
of the offering of the Securities, (iii) can bear the economic risk of a total loss of its investment in the Securities and (iv)
has such knowledge and experience in business and financial matters so as to enable it to understand the risks of and form an investment
decision with respect to its investment in the Securities. The Purchaser has received no representation or warranties from the
Company, its employees, agents, or attorneys in making this investment decision other than as set forth in the Transaction Documents.

 

(e)         
Reliance on Exemptions. At the time such Purchaser was offered the Securities, it was, and as of the date hereof
it is, and on each date on which it exercises any Warrants, it will be either: (i) an “accredited investor” as defined
in Rule 501(a) under the Securities Act or (ii) a “qualified institutional buyer” as defined in Rule 144A(a) under
the Securities Act. The Purchaser understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of the Securities Act and that the Company is relying upon the truth and accuracy of, and the
Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Purchaser
set forth in this Agreement in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire
the Securities.

 

    -12- 

     

    

 

(f)         
No Governmental Review. The Purchaser understands that no United States federal or state agency or any other government
or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability
of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(g)        
Authorization; Enforcement; Validity. The Purchaser is an entity duly organized and validly existing under the laws
of the jurisdiction of its organization with full right, corporate or limited partnership power and authority to enter into and
to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. The execution,
delivery and performance by the Purchaser of the transactions contemplated by this Agreement has been duly authorized by all necessary
corporate or limited partnership action on the part of the Purchaser and any other governmental action with respect to the Purchaser.
 This Agreement has been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with terms hereof,
will constitute the valid and legally binding obligation of the Purchaser, enforceable against it in accordance with its terms,
except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’ rights and remedies.

 

(h)        
No Conflicts. The execution, delivery and performance of this Agreement by the Purchaser and the consummation by
the Purchaser of the transactions contemplated hereby do not and will not (i) result in a violation of the Purchaser’s charter,
bylaws, or other similar organizational documents; (ii) conflict with, or constitute a default (or an event which with notice or
lapse of time or both would become a default) under any agreement, indenture or other instrument, obligation or understanding to
which the Purchaser is a party; or (iii) result in a violation of any law, rule, regulation, order, judgment or decree applicable
to the Purchaser, except for such conflicts, defaults and violations as described in clauses (ii) or (iii) of this sentence as
would not, individually or in the aggregate, have or result in a material adverse effect on the Purchaser.

 

		5.	RESTRICTIONS ON TRANSFER

 

(a)         
Resales. Each Purchaser agrees that the Securities may only be sold or transferred (i) pursuant to an effective registration
statement under the Securities Act (including the Registration Statement (as defined in the Registration Rights Agreement)), or
(ii) pursuant to an exemption from registration under the Securities Act.

 

(b)        
Rule 144. Each Purchaser is aware of Rule 144 promulgated by the SEC pursuant to the Securities Act (as such rule
may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially
the same purpose and effect as such rule, “Rule 144”) and the restrictions imposed thereby and further understands
and agrees that so long as such Purchaser beneficially owns 10% or more of the Company’s then outstanding securities or has
a designee selected by the Purchaser serving on the Board, the Company will deem the Purchaser to be an “affiliate”
as defined in Rule 144(a)(1) and any transfers of the Securities by the Purchaser shall be subject to the limitations applicable
to affiliates set forth in the Securities Act and the rules promulgated thereunder, including without limitation Rule 144.

 

    -13- 

     

    

 

(c)         
Legends. Each Purchaser agrees to the imprinting, so long as is required by this Section 5, of a legend on any of
the Securities in substantially the following form:

 

“THIS SECURITY HAS NOT BEEN REGISTERED
WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION
NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS
EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE
TO THE COMPANY. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER
LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT
OR OTHER LOAN SECURED BY SUCH SECURITIES.”

 

The Company acknowledges and agrees that a Purchaser may from
time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some
or all of the Securities to a financial institution that is an “accredited investor” as defined in Rule 501(a) under
the Securities Act and who agrees to be bound by the provisions of this Agreement and the Registration Rights Agreement and, if
required under the terms of such arrangement, such Purchaser may transfer pledged or secured Securities to the pledgees or secured
parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the
pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge.
At the appropriate Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or
secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including, if the
Securities are subject to registration pursuant to the Registration Rights Agreement, the preparation and filing of any required
prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to appropriately
amend the list of Selling Stockholders (as defined in the Registration Rights Agreement) thereunder.

 

(d)        
Legend Removal. The Company shall cause its counsel to promptly issue a legal opinion to the transfer agent for the
Common Stock with respect to removal of the legend set forth in Section 5(c) above, (i) following any sale of such Shares or Warrant
Shares pursuant to an effective registration statement, (ii) following any sale of such Shares or Warrant Shares pursuant to Rule
144, or (iii) when such Shares or Warrant Shares may be sold under Rule 144, without the requirement for the Company to be in compliance
with the current public information required under Rule 144 as to such Shares and Warrant Shares and without volume or manner-of-sale
restrictions.

 

    -14- 

     

    

 

		6.	BOARD COMPOSITION

 

(a)         
Board Composition; Appointment of Director Designees. The Board shall take all actions necessary such that the Board
shall consist of eight (8) members and shall be composed as follows:

 

(i)the Class I directors with a term ending at
the 2016 annual meeting of stockholders shall consist of one independent director (currently William C. Mills III) and one director
designated by Pyxis Innovations Inc. (currently Joseph M. Landstra) (a “Pyxis Designee”);

 

(ii)the Class II directors with a term ending
at the 2017 annual meeting of stockholders shall consist of the Company’s Chief Executive Officer (currently Mark B. Carbeau),
Kenneth S. Kornman, Ph.D., the Company’s founder and Chief Scientific Officer (for so long as Dr. Kornman remains employed
by the Company), and one director designated by Bay City Capital Fund V, L.P. (currently Dayton Misfeldt) (a “BCC Designee”);
and

 

(iii)the Class III directors with a term ending
at the 2018 annual meeting of stockholders shall consist of one director designated by Pyxis Innovations Inc. (currently Roger
C. Colman) (a “Pyxis Designee”), one independent director (currently James Weaver), and one director designated
by Bay City Capital Fund V, L.P. (currently Lionel Carnot) (a “BCC Designee”).

 

The Pyxis Designees and the BCC Designees, shall be collectively
referred to herein as the “Director Designees.” Each of the shareholders entitled to designate a director hereunder
is referred to herein as a “Designor.” The rights provided under this Section 6 are the exclusive rights of
each such Designor and are not transferable.

 

(b)        
Nominations of Director Designees. For so long as a Designor’s ownership of the outstanding Common Stock of
the Company is at least five percent (5%), any Director Designee (including any successor pursuant to Subsection 6(c) below) designated
by such Designor shall be nominated by the Board of Directors (or a committee thereof) for election at the annual meeting of stockholders
at which such Director Designee’s term will expire. At least ninety (90) days prior to any such annual meeting at or by which
directors are to be elected, such Designor shall notify the Company in writing of the Director Designee to be nominated for election
as a director. The Company shall disclose in its proxy the nominated Director Designee(s). In the absence of any such notification,
it shall be presumed that the Designor’s then incumbent Director Designee(s) has been designated.

 

(c)         
Successor Director Designees. If a Director Designee shall cease to serve as a director for any reason, the Designor
of such Director Designee shall notify the Company in writing of the individual to replace such Director Designee, and the Company’s
Board of Directors shall appoint and elect such replacement director to serve out the remaining term of the existing director.

 

    -15- 

     

    

 

(d)        
Indemnification Agreements. The Company shall enter into an Indemnification Agreement with each successor Director
Designee prior to the commencement of his or her service on the Board.

 

(e)         
Committees of the Board of Directors. For so long as the Designor of the BCC Designees has the right to designate
Director Designees and provided that such individuals meet the requirements imposed by the SEC or any exchange upon which the Common
Stock may be traded for membership on such committees, the Board shall appoint a BCC Designee to the Audit Committee, the Compensation
Committee and the Nominating and Governance Committee. For so long as the Designor of the Pyxis Designees has the right to designate
Director Designees and provided that such individual meets the requirements imposed by the SEC or any exchange upon which the Common
Stock may be traded for membership on such committee, the Board shall appoint a Pyxis Designee to the Audit Committee.

 

(f)         
Amendment of this Section 6. For so long as Pyxis Innovations Inc. has the right to designate a Pyxis Designee, no
provision of this Section 6 may be waived, modified, supplemented or amended except in a written instrument signed, in the case
of an amendment, by the Company, the Purchasers holding at least a majority in interest of the Shares then outstanding (which amendment
shall be binding on all Purchasers) and Pyxis Innovations Inc. or, in the case of a waiver, by the party against whom enforcement
of any such waived provision is sought. For so long as Bay City Capital Fund V, L.P. has the right to designate a BCC Designee,
no provision of this Section 6 may be waived, modified, supplemented or amended except in a written instrument signed, in the case
of an amendment, by the Company, the Purchasers holding at least a majority in interest of the Shares then outstanding (which amendment
shall be binding on all Purchasers) and Bay City Capital Fund V, L.P. or, in the case of a waiver, by the party against whom enforcement
of any such waived provision is sought.

 

(g)        
Board Observer Rights. For so long as a Growth Equity Opportunities Fund III, LLC’s (“GEOF”)
ownership of the outstanding Common Stock of the Company is at least five percent (5%), GEOF shall have the right to have a representative
(the “Observer”) attend each meeting of the Board. The Company shall deliver to the Observer notice of such
meetings in accordance with the Company’s Bylaws. Copies of any materials distributed to members of the Board shall likewise
be provided to the Observer in a timely fashion. The Company shall not be required to deliver to the Observer specific information,
and may preclude the Observer from specific discussions of the Board of Directors concerning specific information, that (i) is
determined by the Board of Directors of the Company to be competitively sensitive, (ii) the Board of Directors of the Company determines
is attorney-client privileged and should not, therefore, be disclosed or (iii) the Board of Directors of the Company determines
is reasonably necessary to preserve or protect the exercise of the Board of Directors’ fiduciary duty or to avoid a possible
conflict of interest. GEOF agrees, and any representative of GEOF, including the Observer, will agree, to hold in confidence and
trust and not disclose (other than to GEOF or its affiliates) or use any confidential information provided to or learned by it
in connection with its rights under this letter, provided, that GEOF may give access to such confidential information to its officers,
directors, employees, accountants, counsel and other representatives (collectively, “Representatives”) if each
such Representative is informed of the confidential nature of the information and that the information is subject to a confidentiality
agreement and each such Representative is otherwise under an obligation to keep such confidential information confidential. Each
Observer shall execute a non-disclosure agreement with the Company in form and substance reasonably satisfactory to the Company
prior to commencing his or her role as an Observer. The rights set forth in this Section 6(g) may not be assigned by GEOF without
the prior written consent of the Company.

 

    -16- 

     

    

 

		7.	OTHER AGREEMENTS AND COVENANTS

 

(a)         
National Market Listing. Following the Closing, the Company will work with the Purchasers and advisors to qualify
for and obtain a full national market listing of its Common Stock on either the NASDAQ Capital Market or the NYSE MKT. The Company
will use commercially reasonable efforts to qualify and apply for such listing, including effecting a reverse split of its common
stock, subject to shareholder approval, if deemed advisable by a majority of the Board.

 

(b)        
Use of Proceeds. The proceeds from the sale of the Shares and Warrants under this Agreement shall be used for working
capital and general corporate purposes.

 

(c)         
Form D; Blue Sky Filings. The Company agrees to timely file a Form D with respect to the Securities as required under
Regulation D and, promptly upon request of any Purchaser, to provide a copy thereof. The Company shall take such action as the
Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to
the Purchasers at each Closing under applicable securities or “Blue Sky” laws of the states of the United States, and
shall provide evidence of such actions promptly upon request of any Purchaser. The Company shall make all filings and reports relating
to the offer and sale of the Securities to the Purchasers required under applicable securities or “Blue Sky” laws of
the states of the United States following each Closing Date.

 

(d)        
Reservation of Shares. As of the date hereof, the Company has reserved and the Company shall continue to reserve
and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling
the Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants, in each case
issued as of the Closing. 

 

(e)         
Exchange Act Filings. Until such time that all of the Securities may be sold without the requirement for the Company
to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, the Company covenants
to use commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace
period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act.

 

(f)         
Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect
of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities
in a manner that would require the registration under the Securities Act of the sale of the Securities or that would be integrated
with the offer or sale of the Securities for purposes of the rules and regulations of any trading market such that it would require
shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing
of such subsequent transaction.

 

    -17- 

     

    

 

(g)        
Expenses. The Company shall pay the reasonable legal and other fees and expenses of the Purchasers incurred in connection
with the transactions contemplated by this Agreement, up to a maximum of $25,000 in the aggregate, whether or not the Closing occurs.
In the event the Closing occurs, the Company shall pay the reasonable legal fees and expenses of the Purchasers incurred in connection
with the transactions contemplated by this Agreement, up to a maximum of $50,000 in the aggregate. Each party shall otherwise bear
all costs and expenses incurred by such party in connection with the transactions contemplated by this Agreement.

 

(h)        
Purchaser/Director Designee Exchange Act Filings.  Each Purchaser and each Director Designee shall be responsible
for the filing (and for all expenses in connection therewith) of required filings under the Exchange Act and all required amendments
thereto relating to ownership of the Securities and appointment as a member of the Board, including any required Forms 3, 4 and
5 and Schedules 13D or 13G (as applicable). Each Purchaser and each Director Designee shall use commercially reasonable efforts
to file such forms within the time period allowed for such forms under the rules and regulations promulgated by the SEC.

 

		8.	PUBLIC STATEMENTS

 

The Company shall, by 9:00 a.m. (New York
City time) on the trading day immediately following the date of this Agreement, issue a press release disclosing the material terms
of the transactions contemplated hereby. The Company shall file a Current Report on Form 8-K within the time required by Form 8-K
disclosing the material terms of the transactions contemplated hereby, which Form 8-K shall include this Agreement (including conformed
signature pages thereto), the Registration Rights Agreement (including conformed signature pages thereto) and the form of Warrant
as exhibits thereto. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect
to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise
make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or
without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably
be withheld or delayed, except if such disclosure is required by law.

 

		9.	MISCELLANEOUS

 

(a)         
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
shall be governed by the internal laws of the State of Delaware, United States of America, without giving effect to any choice
of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdictions) that would cause the
application of the laws of any jurisdictions other than the State of Delaware. If any provision of this Agreement shall be invalid
or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the
remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in any other
jurisdiction.

 

    -18- 

     

    

 

(b)        
Entire Agreement. This Agreement and the documents referenced herein and therein constitute the entire agreement
among the parties hereto with respect to the subject matter hereof and thereof. There are no restrictions, promises, warranties
or undertakings, other than those set forth or referred to herein and therein. This Agreement and the documents referenced herein
and therein supersede all prior agreements and understandings among the parties hereto with respect to the subject matter hereof
and thereof. Without limiting the foregoing, it is acknowledged and agreed that Section 6 of this Agreement (as it may be amended
from time to time) shall supersede and replace (i) Section 6 of the Common Stock Purchase Agreement, dated May 17, 2013, by and
among the Company and the purchasers signatory thereto, as amended on March 31, 2014, May 30, 2014 and April 6, 2015 and (ii) Section
6 of the Common Stock Purchase Agreement, dated December 23, 2014, by and among the Company and the purchasers signatory thereto,
as amended on April 6, 2015. Notwithstanding the foregoing, the terms of any confidentiality agreement entered into between the
Company and any Purchaser shall remain in full force and effect.

 

(c)         
Amendments and Waivers. Except as otherwise set forth herein, no provision of this Agreement may be waived, modified,
supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding
at least a majority in interest of the Shares then outstanding (which amendment shall be binding on all Purchasers) or, in the
case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default with respect
to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver
of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission
of any party to exercise any right hereunder in any manner impair the exercise of any such right.

 

(d)        
Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms
of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii)
upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept
on file by the sending party); (iii) upon receipt when delivered by email delivery of a “.pdf” format data file or
(iv) upon receipt, when sent via a nationally recognized overnight delivery service, in each case properly addressed to the party
to receive the same. The addresses, facsimile numbers and email addresses for such communications shall be:

 

	 	If to the Company: 	Interleukin Genetics, Inc.
	 	 	135 Beaver Street
	 	 	Waltham, MA 02452
	 	 	Telephone:  	(781) 398-0700
	 	 	Facsimile:	(781) 398-0720
	 	 	email:	mcarbeau@ilgenetics.com
	 	 	Attention: 	Mark B. Carbeau
	 	 	 	Chief Executive Officer
	 	with a copy to:	 	 
	 	 	 	 
	 	 	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
	 	 	One Financial Center Boston, MA 02111
	 	 	Tel:	(617) 542-6000
	 	 	Fax:	(617) 542-2241
	 	 	email:	bkeane@mintz.com
	 	 	Attn: 	Brian P. Keane, Esq.  
	 	 	 	 
	 	If to a Purchaser: 	To the address set forth on the signature page to this Agreement.

 

    -19- 

     

    

 

(e)         
No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties
to express their mutual intent, and no rules of strict construction will be applied against any party.

 

(f)         
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and
things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may
reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

(g)        
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein
shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use
their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result
as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention
of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any
of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

(h)        
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written
consent of each Purchaser (other than by merger, consolidation or sale of all or substantially all of the Company’s assets).
Except as specifically set forth herein, any Purchaser may assign any or all of its rights under this Agreement to any Person to
whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect
to the transferred Securities, by the provisions of this Agreement and the documents referenced herein that apply to the Purchasers.

 

(i)          
Survival. Subject to applicable statute of limitations, the representations and warranties contained herein shall
survive the Closing and the delivery of the Securities hereunder. No investigation by or knowledge of a party or its representatives,
before or after the date of this Agreement, will affect in any manner the representations, warranties, covenants or agreements
of another party set forth in this Agreement (or in any document to be delivered in connection with the consummation of the transactions
contemplated by this Agreement) or the rights to rely thereon, and such representations, warranties, covenants and agreements will
survive any such investigation.

 

    -20- 

     

    

 

(j)          
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective
successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person or
entity.

 

(k)        
Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen
or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in
the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence
reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under
such circumstances shall also pay any reasonable third-party costs (including customary indemnity or bond) associated with the
issuance of such replacement Securities.

 

(l)          
Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under this Agreement
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the
performance or non-performance of the obligations of any other Purchaser under this Agreement. Nothing contained herein or in any
other document referred to herein, and no action taken by any Purchaser pursuant hereof or thereto, shall be deemed to constitute
the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the
Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by
this Agreement. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation,
the rights arising out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party
in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of this Agreement and the other documents referred to herein.

 

(m)      
Business Day. “Business Day” means any day except any Saturday, any Sunday, any day which is a
federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or
required by law or other governmental action to close. If the last or appointed day for the taking of any action or the expiration
of any right required or granted herein or in the Registration Rights Agreement shall not be a Business Day, then such action may
be taken or such right may be exercised on the next succeeding Business Day.

 

(n)        
Headings. The headings of this Agreement are for convenience of reference only and shall not limit or otherwise affect
the meaning hereof.

 

(o)        
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be
considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered
to each other party, it being understood that the parties need not sign the same counterpart. In the event that any signature is
delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create
a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect
as if such facsimile or “.pdf” signature page were an original thereof.

 

    -21- 

     

    

 

[Remainder of page intentionally left
blank. Signature pages follow.]

 

    -22- 

     

    

 

IN WITNESS WHEREOF, the parties hereto have
caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.

 

	 	COMPANY:
	 	INTERLEUKIN GENETICS, Inc.
	 	 
	 	 
	 	By:	/s/ Mark B. Carbeau
	 	 	Name:  Mark B. Carbeau

Title:  Chief Executive Officer

 

 

[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK.

SIGNATURE PAGES FOR PURCHASERS FOLLOW.]

 

    

     

    

 

[PURCHASER SIGNATURE PAGES TO INTERLEUKIN
GENETICS, INC. 

SECURITIES
PURCHASE AGREEMENT]

 

IN WITNESS WHEREOF,
the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

	Name of Purchaser:  	 

 

	Signature of Authorized Signatory of Purchaser:   	 

 

	Name
of Authorized Signatory:  	 

 

	Title
of Authorized Signatory:  	 

 

	Email
Address for Notice to Purchaser:  	 

 

	Facsimile
Number for Notice to Purchaser:  	 

 

	Address for Notice to Purchaser:  	 

 

 

Address for Delivery of Securities to Purchaser (if not same
as address for notice):

 

  

 

Purchase Price: $_________________

 

Shares of Common Stock: _________________

 

Warrant Shares: __________________

 

EIN Number: __________________

 

 

 

[SIGNATURE PAGES CONTINUE]

 

    

     

    

 

SCHEDULE I

 

The Purchasers

 

	Purchaser
	 	Shares
	 	 	Warrants
	 	 	Purchase Price	 
	Bay City Capital Fund V, L.P	 	 	29,616,700	 	 	 	29,616,700	 	 	$	2,943,899.98	 
	Bay City Capital Fund V Co-Investment Fund, L.P.	 	 	564,386	 	 	 	564,386	 	 	$	56,099.97	 
	Growth Equity Opportunities Fund III, LLC	 	 	20,120,724	 	 	 	20,120,724	 	 	$	1,999,999.97	 
	Pyxis Innovations, Inc.	 	 	5,030,181	 	 	 	5,030,181	 	 	$	499,999.99	 
	William Alan Jolley	 	 	503,018	 	 	 	503,018	 	 	$	49,999,99	 
	Weaver Asset Management, LLC	 	 	100,603	 	 	 	100,603	 	 	$	9,999.94	 
	Mark B. Carbeau	 	 	100,603	 	 	 	100,603	 	 	$	9,999.94	 
	Kenneth S. Kornman	 	 	25,150	 	 	 	25,150	 	 	$	2,499.91	 
	Lynn Doucette-Stamm	 	 	100,603	 	 	 	100,603	 	 	$	9,999.94	 
	Stephen DiPalma	 	 	100,603	 	 	 	100,603	 	 	$	9,999.94	 
	Total	 	 	56,262,571	 	 	 	56,262,571	 	 	$	5,592,499.57	 

 

    

     

    

 

EXHIBIT A

 

See Exhibit 4.1 to the Form 8-K filed on August 1, 2016 (File
No. 001-32715)

 

    

     

    

 

EXHIBIT B

 

See Exhibit 10.2 to the Form 8-K filed on August 1, 2016 (File
No. 001-32715)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00260-of-00352.parquet"}]]